2 results
Approved WMOCompleted
Primary Objective To determine whether the combination of Onartuzumab + * erlotinib is superior (in terms of OS) to placebo * erlotinib after standard platinum-based chemotherapy in patients with Met diagnostic*positive non*small cell lung cancer (…
Approved WMOCompleted
To evaluate the efficacy of each combination arm, as measured by confirmed objective response rate (ORR)